The primary objective of the study was assessment of the efficacy of four dose reservoirs (25 mcg, 50 mcg, 100 mcg, 200 mcg) of intravaginal controlled release misoprostol administered for up to 24 hours. Efficacy was measured in terms of time from insert placement to vaginal delivery.
Approximately 20% of pregnant women require medical intervention to induce labour for reasons including post-date pregnancy, pre-eclampsia, maternal diabetes, premature rupture of the membranes and intra-uterine fetal growth retardation. There are two fundamental changes that characterise pre-labour preparation for delivery: sensitisation of the myometrium to produce contractions, and ripening (softening and dilation) of the cervix. Prostaglandins (PG) are fundamental to both of these changes, and several forms have been used to successfully induce labour. Dinoprostone (PGE2) is an example of a cervical ripening agent that is available in gel and tablet form and has a proven record of successful cervical ripening in this population. Dinoprostone is also available in a controlled release vaginal delivery system, which is manufactured by Controlled Therapeutics (Scotland) a subsidiary of Cytokine PharmaSciences, Inc., King of Prussia, PA, USA. Another synthetic prostaglandin that has been shown to be an effective cervical ripener and labour inducer is misoprostol. Oral tablets are broken into fragments and used intravaginally to ripen the cervix and induce labour Due to the disadvantages of existing cervical ripeners (delivery of bolus doses, freezer or refrigerated storage, lack of efficacy in labour induction), and due to safety concerns with the off-label use of oral misoprostol tablet fragments, Controlled Therapeutics has developed a controlled release vaginal delivery system similar to its marketed dinoprostone product but containing misoprostol. This study examines four dose strengths of the misoprostol vaginal insert in women who need to have their labours induced.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
124
One hydrogel polymer vaginal insert for up to 24h
One hydrogel polymer vaginal insert for up to 24h
One hydrogel polymer vaginal insert for up to 24h
Birmingham Women's Hospital
Birmingham, United Kingdom
Princess Royal Maternity Hospital
Glasgow, United Kingdom
King George Hospital
Ilford, United Kingdom
Liverpool Women's Hospital
Liverpool, United Kingdom
Time to vaginal delivery.
Time frame: From insertion of study drug to neonate delivery
uterine hyperstimulation
Time frame: From insertion of study drug to neonate delivery
safety in terms of maternal, fetal and neonatal adverse events
Time frame: From insertion of study drug to neonate delivery
Success on composite modified Bishop score (MBS)at 12 hours after drug insertion
Time frame: From insertion of study drug to 12 hours
frequency and amount of oxytocin use
Time frame: From insertion of study drug to neonate delivery
drug release characteristics in terms of residual concentrations
Time frame: From insertion of study drug to removal of study drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One hydrogel polymer vaginal insert for up to 24h
Northampton General Hospital
Northampton, United Kingdom
The Queen's Mother's Hospital
Yorkhill, Glasgow, United Kingdom